Literature DB >> 19660848

Serum cystatin C for prediction of dialysis requirement or death in acute kidney injury: a comparative study.

Mary C Perianayagam1, Victor F Seabra, Hocine Tighiouart, Orfeas Liangos, Bertrand L Jaber.   

Abstract

BACKGROUND: Serum cystatin C has emerged as a new and potentially more reliable marker of kidney function. However, its utility and performance in patients with acute kidney injury (AKI), particularly for the prediction of dialysis requirement, is not well known. STUDY
DESIGN: Prospective cohort study. SETTINGS & PARTICIPANTS: Adult patients with AKI enrolled at 2 academic medical centers, at time of nephrology consultation. PREDICTORS: Serum cystatin C (primary predictor), serum creatinine, and serum urea nitrogen levels and 24-hour urine output measured at enrollment. OUTCOMES: The composite of dialysis requirement or in-hospital death. COVARIATES: Acute Physiology and Chronic Health Evaluation II (APACHE II) score, liver disease, sepsis, and mechanical ventilation.
RESULTS: 200 participants were enrolled for this analysis. Mean age was 65 years, 55% were men, and mean APACHE II score was 20. In unadjusted analyses, increases in serum cystatin C (odds ratio [OR], 1.87; 95% confidence interval [CI], 1.36 to 2.59), serum creatinine (OR, 1.53; 95% CI, 1.12 to 2.09), and serum urea nitrogen levels (OR, 1.84; 95% CI, 1.34 to 2.54) were associated with a higher odds (per 1-SD increase) for the composite outcome, whereas greater urine output (OR, 0.56; 95% CI, 0.39 to 0.80) was associated with lower odds. These associations persisted after adjustment for APACHE II score. The addition of serum cystatin C, serum creatinine, and serum urea nitrogen levels or urine output to a basic model entailing APACHE II score, liver disease, sepsis, and assisted mechanical ventilation improved its prediction, evidenced by increases in areas under a receiver operator characteristic curve from 0.816 to 0.829, 0.826, 0.837, and 0.836, respectively. However, there was no significant difference between each of these models. LIMITATIONS: Observational study, single serum cystatin C measurement.
CONCLUSION: In patients with AKI, serum cystatin C level performs similarly to serum creatinine level, serum urea nitrogen level, and urine output for predicting dialysis requirement or in-hospital death. Larger studies are needed to confirm these findings.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19660848     DOI: 10.1053/j.ajkd.2009.05.022

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  18 in total

1.  Cystatin C is a moderate predictor of acute kidney injury in the early stage of traumatic hemorrhagic shock.

Authors:  Shu Chen; Jing-Song Shi; Xiaokaiti Yibulayin; Tian-Shan Wu; Xin-Wen Yang; Jie Zhang; Paerhati Baiheti
Journal:  Exp Ther Med       Date:  2015-04-23       Impact factor: 2.447

2.  Biomarkers for AKI improve clinical practice: no.

Authors:  Marlies Ostermann; Michael Joannidis
Journal:  Intensive Care Med       Date:  2014-11-12       Impact factor: 17.440

3.  Guiding Physician Decisions for Initiating Dialysis for AKI: Is Progress on the Horizon?

Authors:  Etienne Macedo; Ravindra L Mehta
Journal:  Clin J Am Soc Nephrol       Date:  2017-01-24       Impact factor: 8.237

Review 4.  Biomarkers of acute kidney injury in children: discovery, evaluation, and clinical application.

Authors:  Zubaida Al-Ismaili; Ana Palijan; Michael Zappitelli
Journal:  Pediatr Nephrol       Date:  2010-07-10       Impact factor: 3.714

5.  Comparison of serum creatinine and serum cystatin C as biomarkers to detect sepsis-induced acute kidney injury and to predict mortality in CD-1 mice.

Authors:  Asada Leelahavanichkul; Ana Carolina P Souza; Jonathan M Street; Victor Hsu; Takayuki Tsuji; Kent Doi; Lingli Li; Xuzhen Hu; Hua Zhou; Parag Kumar; Jürgen Schnermann; Robert A Star; Peter S T Yuen
Journal:  Am J Physiol Renal Physiol       Date:  2014-08-20

Review 6.  Cystatin C: a step forward in assessing kidney function and cardiovascular risk.

Authors:  Johan Lassus; Veli-Pekka Harjola
Journal:  Heart Fail Rev       Date:  2012-03       Impact factor: 4.214

Review 7.  Update on biomarkers of acute kidney injury: moving closer to clinical impact?

Authors:  Helmut Schiffl; Susanne M Lang
Journal:  Mol Diagn Ther       Date:  2012-08-01       Impact factor: 4.074

8.  Serum interleukin-18 at commencement of renal replacement therapy predicts short-term prognosis in critically ill patients with acute kidney injury.

Authors:  Chan-Yu Lin; Chih-Hsiang Chang; Pei-Chun Fan; Ya-Chung Tian; Ming-Yang Chang; Chang-Chyi Jenq; Cheng-Chieh Hung; Ji-Tseng Fang; Chih-Wei Yang; Yung-Chang Chen
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

Review 9.  Clinical review: Biomarkers of acute kidney injury: where are we now?

Authors:  Marlies Ostermann; Barbara J Philips; Lui G Forni
Journal:  Crit Care       Date:  2012-09-21       Impact factor: 9.097

10.  Cohort profile: Canadian study of prediction of death, dialysis and interim cardiovascular events (CanPREDDICT).

Authors:  Adeera Levin; Claudio Rigatto; Barrett Brendan; François Madore; Norman Muirhead; Daniel Holmes; Catherine M Clase; Mila Tang; Ognjenka Djurdjev
Journal:  BMC Nephrol       Date:  2013-06-11       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.